Show simple item record

dc.contributor.authorSommen, Silke Lauren
dc.contributor.authorHavdal, Lise Beier
dc.contributor.authorSelvakumar, Joel Pradeepkumar
dc.contributor.authorEinvik, Gunnar
dc.contributor.authorLeegaard, Truls Michael
dc.contributor.authorLund-Johansen, Fridtjof
dc.contributor.authorMichelsen, Annika Elisabet
dc.contributor.authorMollnes, Tom Eirik
dc.contributor.authorStiansen-Sonerud, Tonje
dc.contributor.authorTjade, Trygve Olav
dc.contributor.authorWyller, Vegard Bruun Bratholm
dc.contributor.authorLund-Berven, Lise
dc.date.accessioned2023-02-22T09:31:39Z
dc.date.available2023-02-22T09:31:39Z
dc.date.created2023-02-17T10:49:25Z
dc.date.issued2022
dc.identifier.citationFrontiers in Immunology. 2022, 13:1081718 1-12.en_US
dc.identifier.issn1664-3224
dc.identifier.urihttps://hdl.handle.net/11250/3053067
dc.description.abstractIntroduction: Both public and scientific attention have shifted from the acute COVID-19 illness to the chronic disability experienced by a proportion of COVID-19 convalescents. Post COVID-19 condition, a term used for long-lasting symptoms after COVID-19, can affect individuals across all disease severity and age groups. Data on post-COVID-19 symptomatology, epidemiology and pathophysiology in adolescents and young adults are scarce. To date, little is known on the immunological and pulmonary trends in these patients after COVID-19. This study investigated immunological markers and pulmonary function in non-hospitalized patients in this group at 6 months after initial mild COVID-19 infection. Methods: Non-hospitalized SARS-CoV-2 positive (n = 405) and SARS-CoV-2 negative (n = 111) adolescents and young adults (aged 12-25 years) were followed prospectively for six months after SARS-CoV-2 PCR testing. At baseline and at six months follow-up, all participants underwent an assessment including clinical examination, questionnaires, spirometry, and blood sampling. Cross-sectional comparisons of blood biomarkers; including white blood cell counts, CRP, GDF-15, a 27-multiplex cytokine assay, complement activation products and SARS-CoV-2 antibodies; and spirometry measures were performed after classification of all participants according to their COVID-19 status and adherence to post-COVID-19 case criteria. Associations between biomarkers and COVID-19 symptoms were explored. Results: No difference in pulmonary function was detected between the groups. COVID-19 convalescents had higher levels of chemokines eotaxin, MCP-1 and IP-10 than non-infected controls. The increase was modest and not associated with long-lasting COVID-19 symptoms. Discussion: Elevated inflammatory mediators were found in adolescents and young adults six months after mild COVID-19, but there was no association with post-COVID-19 condition.en_US
dc.language.isoengen_US
dc.publisherFrontiers Mediaen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleInflammatory markers and pulmonary function in adolescents and young adults 6 months after mild COVID-19en_US
dc.title.alternativeInflammatory markers and pulmonary function in adolescents and young adults 6 months after mild COVID-19en_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber1-12en_US
dc.source.volume13:1081718en_US
dc.source.journalFrontiers in Immunologyen_US
dc.identifier.doi10.3389/fimmu.2022.1081718
dc.identifier.cristin2126909
dc.relation.projectNorges forskningsråd: 223255en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal